IL285772A - Treatment with p2x3 modulators - Google Patents

Treatment with p2x3 modulators

Info

Publication number
IL285772A
IL285772A IL285772A IL28577221A IL285772A IL 285772 A IL285772 A IL 285772A IL 285772 A IL285772 A IL 285772A IL 28577221 A IL28577221 A IL 28577221A IL 285772 A IL285772 A IL 285772A
Authority
IL
Israel
Prior art keywords
modulators
treatment
Prior art date
Application number
IL285772A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc filed Critical Bellus Health Cough Inc
Publication of IL285772A publication Critical patent/IL285772A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL285772A 2019-02-25 2021-08-22 Treatment with p2x3 modulators IL285772A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962810163P 2019-02-25 2019-02-25
PCT/IB2020/000160 WO2020174283A1 (en) 2019-02-25 2020-02-24 Treatment with p2x3 modulators

Publications (1)

Publication Number Publication Date
IL285772A true IL285772A (en) 2021-10-31

Family

ID=72239247

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285772A IL285772A (en) 2019-02-25 2021-08-22 Treatment with p2x3 modulators

Country Status (8)

Country Link
US (1) US12485125B2 (enExample)
EP (1) EP3930722A4 (enExample)
JP (1) JP7578602B2 (enExample)
CN (1) CN113727716A (enExample)
AU (1) AU2020228760A1 (enExample)
CA (1) CA3131312A1 (enExample)
IL (1) IL285772A (enExample)
WO (1) WO2020174283A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3930722A4 (en) 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS
IL295393A (en) * 2020-02-14 2022-10-01 Bellus Health Cough Inc P2x3 modulators
CN113754654A (zh) * 2020-06-05 2021-12-07 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN116635389A (zh) * 2021-01-29 2023-08-22 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
CN115043836B (zh) * 2021-08-20 2023-07-18 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
GB202212749D0 (en) * 2022-09-01 2022-10-19 Gesynta Pharma Ab New uses

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH503559A (de) 1969-02-26 1971-02-28 Arx Paul Von Vorrichtung an Tafelschere zum Schneiden nach Markierungen, unter ständiger Beobachtung des Schnittes
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
TR200500745T2 (tr) 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
WO2002085309A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
SE0102808D0 (sv) 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー P2x3受容体活性のモジュレーター
RU2542582C2 (ru) * 2009-11-18 2015-02-20 Астразенека Аб Производные бензимидазола, полезные при лечении состояний, ассоциированных с активностью р2х3 или р2х2/3
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
US9526718B2 (en) 2011-06-28 2016-12-27 Vivozon, Inc. Combination of effective substances causing synergistic effects of multiple targeting and use thereof
KR102120513B1 (ko) 2013-01-31 2020-06-08 네오메드 인스티튜트 이미다조피리딘 화합물 및 이의 용도
US9937815B2 (en) 2013-08-15 2018-04-10 Volvo Truck Corporation Method and arrangement for balancing an energy storage system
MX367657B (es) 2013-08-23 2019-08-30 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
DK3587417T3 (da) * 2014-12-09 2022-03-28 Bayer Ag 1,3-thiazol-2-yl-substituerede benzamider
WO2017058645A1 (en) 2015-09-29 2017-04-06 Afferent Pharmaceuticals, Inc. Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
EP3430000B1 (en) 2016-03-14 2022-12-28 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
EP3528813B1 (en) 2016-09-30 2025-04-16 ABS Development 1, Inc. P2x3 and/or p2x2/3 compounds and methods
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
HUE071480T2 (hu) * 2018-11-13 2025-08-28 Glaxosmithkline Intellectual Property No 3 A P2X3-modulátor metil (S)-2-((2-(2,6-difluoro-4-(metil-karbamoil)fenil)-7-metilimidazo[1,2-a] piridin-3-il)metil)morfolin-4-karboxilát kristályos formái
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
AU2019416589B2 (en) 2018-12-29 2023-04-06 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound intermediate, preparation method therefor and application thereof
EP3930722A4 (en) 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS
IL295393A (en) 2020-02-14 2022-10-01 Bellus Health Cough Inc P2x3 modulators
US20230101612A1 (en) 2020-02-14 2023-03-30 Bellus Health Cough Inc. Preparation of a p2x3 antagonist

Also Published As

Publication number Publication date
US20210386751A1 (en) 2021-12-16
CA3131312A1 (en) 2020-09-03
WO2020174283A1 (en) 2020-09-03
US12485125B2 (en) 2025-12-02
CN113727716A (zh) 2021-11-30
AU2020228760A1 (en) 2021-09-23
EP3930722A1 (en) 2022-01-05
EP3930722A4 (en) 2022-12-28
JP2022521955A (ja) 2022-04-13
JP7578602B2 (ja) 2024-11-06

Similar Documents

Publication Publication Date Title
EP3994692C0 (en) BINARY COMPUTING CELL IN MEMORY
DK3743406T3 (da) Tmem16a modulatorer
EP3833739A4 (en) STRAIN OF AKKERMANSIA MUCINIPHILA
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
EP3684368A4 (en) SELECTIVE P2X3 MODULATORS
IL285772A (en) Treatment with p2x3 modulators
EP3852689A4 (en) SURGERY PROCESS
HUE062866T2 (hu) TREX-1 modulátorok
EP3899024A4 (en) Modulators of hsd17b13 expression
EP3919491C0 (en) AKT INHIBITOR
EP4103564A4 (en) P2X3 MODULATORS
DK3749669T3 (da) Ahr-modulatorer
EP3967649C0 (en) LIPID NANOPARTICLE
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
IL285074A (en) Gpr35 modulators
EP3972610A4 (en) MINI-GENE THERAPY
EP4035739A4 (en) HYDROGEL
EP3975220A4 (en) Display panel
EP3973348A4 (en) HEAD MOUNT DISPLAYS
EP3957391C0 (en) AGITATOR
EP3779540A4 (en) Optical modulator
EP3912517C0 (en) FRAME
IL281839A (en) Treatment methods
IL281792A (en) Treatment methods
EP4025957C0 (en) ELECTRO-OPTIC MODULATOR